The European Commission has been working hard over the summer to implement its 17 June strategy to build up a pipeline of candidate vaccines against Covid-19 (see EUROPE B12508A4).
During the summer, it has in turn concluded preliminary discussions with Sanofi-GSK, Johnson&Johnson and Curevac. It has also entered into an advance purchase agreement with the pharmaceutical company AstraZeneca. On Monday 24 August, it added another brick in the wall by announcing that it had finalised its...